Drug intelligence / Profile preview

dropropizine + pseudoephedrine + brompheniramine

Development stage
Unknown
Lead developer
Dompé
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a **combination product** containing **dropropizine** (a non-opioid antitussive/cough suppressant), **pseudoephedrine** (a sympathomimetic amine serving as a nasal decongestant via vasoconstriction through alpha- and beta-adrenergic receptor agonism[4]), and **brompheniramine** (an antihistamine that antagonizes histamine H1 receptors). The combination is indicated primarily for the symptomatic treatment of **cough** and **nasal congestion** associated with the **common cold** or **upper respiratory tract infections**, especially in pediatric populations[5][7]. - Dropropizine acts centrally to suppress cough reflex - Pseudoephedrine decreases nasal congestion by vasoconstriction in nasal mucosa - Brompheniramine relieves allergic symptoms by blocking H1 histamine receptors Primary use is for cough and cold symptom relief, typically as an oral syrup, such as in Dimetapp elixir[5][7].

Brand names
Dimetapp elixir
Other names
dropropizine + pseudoephedrine hydrochloride + brompheniramine maleate
02

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on dropropizine + pseudoephedrine + brompheniramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dropropizine + pseudoephedrine + brompheniramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call